The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months.
The main questions this study is asking are:
* Does TMP-SMX lower the number of UTIs in the first year after transplant?
* What side effects or problems do participants have while taking TMP-SMX?
Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs.
Participants will:
* Take either TMP-SMX or a placebo pill by mouth every day for 6 months
* Have three visits to touch base with the study team about any issues
* Complete short monthly online surveys about any symptoms or side effects
* Share blood and urine test results from their regular transplant clinic visits

Start Date01 Nov 2026

Sponsor / Collaborator

The University of California, San Francisco

NCT07224997

/ Not yet recruitingPhase 2IIT

Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections

Official Title
Trimethoprim-Sulfamethoxazole (TMP/SMX) Prophylaxis After Acute Kidney Injury to Prevent Post-discharge Infections: A Randomized, Double-Blind, Placebo-Controlled Trial
Brief Summary
Acute kidney injury (AKI) is commonly followed by infections after hospital discharge. This randomized, double-blind, placebo-controlled trial will test whether prophylactic TMP/SMX reduces post-discharge infections in adults recently hospitalized with AKI. Participants will be randomized 1:1 to TMP/SMX or matching placebo and followed for 6 months. The primary outcome is the proportion of participants who develop any infection within 90 days after discharge. Secondary outcomes include time to first infection, infection-related hospitalization, mortality, safety/adverse events, and healthcare utilization through 180 days.
Detailed Description
Adults discharged after an index hospitalization complicated by AKI are at elevated infection risk. This trial evaluates whether short-term TMP/SMX prophylaxis reduces 90-day infections. After consent and eligibility confirmation near discharge, participants are randomized (1:1) to receive TMP/SMX or matching placebo with double-blind masking (participant and outcome assessor). Dosing is standardized per protocol. We will ascertain infections via structured follow-up, medical record review, and adjudication by blinded assessors. Safety monitoring will capture adverse events (e.g., rash, cytopenias, hyperkalemia). Analyses follow intention-to-treat.
Study Design
* Study Type: Interventional (Clinical Trial)
* Primary Purpose: Prevention
* Allocation: Randomized (1:1)
* Intervention Model: Parallel Assignment
* Masking: Double-blind (Participant, Outcomes Assessor)
* Estimated Enrollment: 60 patients per group
* Study Start Date: December 2025
* Primary Completion Date (Anticipated): January 2027 (last patient reaches 90-day outcome)
* Study Completion Date (Anticipated): July 2028 (last patient completes 180-day follow-up)
Arms & Interventions
Experimental: TMP/SMX
* Intervention: Drug: Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours
* Dosing: One tablet by mouth, Trimethoprim-Sulfamethoxazole (TMP/SMX) 160/800 mg tablets every 48 hours, for 90 days post-discharge.
* Other names: cotrimoxazole, sulfamethoxazole-trimethoprim. Bactrim F
Placebo Comparator: Placebo
* Intervention: Drug: Placebo (matching oral tablet)
* Dosing: Matching schedule for 90 days post-discharge.
Concomitant care: Allowed per treating clinician. Drug interactions and lab monitoring handled per protocol.
Outcome Measures
Primary Outcome
• Any infection within 90 days after discharge Time Frame: Day 0 (discharge) to Day 90 Measure: Proportion of participants with ≥1 infection, defined by clinical diagnosis requiring documentation (e.g., UTI, pneumonia, SSTI, bloodstream infection) and/or antimicrobial treatment initiation.
Secondary Outcomes
1. Time to first infection (days) within 90 days.
2. Infection-related hospitalization within 90 and 180 days.
3. All-cause mortality at 90 and 180 days.
4. Emergency department visits or unplanned readmissions within 180 days.
5. Antibiotic-related adverse events (rash, cytopenia, creatinine rise ≥0.3 mg/dL, hyperkalemia ≥5.5 mmol/L) through 180 days.
6. C. difficile infection within 180 days.
7. Recurrent AKI (KDIGO criteria) within 180 days.
8. Medication adherence (pill counts and/or self-report) over 90 days.
9. Major adverse kidney events over 90 days.
Eligibility Criteria
Inclusion Criteria
* Age ≥18 years.
* Index hospitalization complicated by AKI (KDIGO criteria) prior to discharge.
* Planned discharge to community/rehabilitation with capacity for follow-up.
* Ability to provide informed consent.
Exclusion Criteria
* Known allergy to sulfonamides or TMP/SMX.
* Pregnancy or breastfeeding.
* Severe hepatic disease (e.g., Child-Pugh C).
* Severe cytopenia (e.g., ANC <1.0×10⁹/L or platelets <50×10⁹/L).
* Baseline hyperkalemia (>5.5 mmol/L) not correctable prior to randomization.
* Concomitant medications with high-risk interactions not amenable to dose/monitoring (per protocol).
* Current systemic antimicrobial therapy planned for >14 days after discharge (prophylaxis not indicated).
* Inability to adhere to study procedures or follow-up.
Contacts/Locations
* Lead Sponsor / Responsible Party: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología
* Principal Investigator: Jonathan Samuel Chavez Iñiguez, Hospital Civil de Guadalajara, servicio de Nefrología, 3313299609
* Study Locations: Hospital Civil de Guadalajara, servicio de Nefrología, Hospital 278, colonia el Retiro. Guadalajara. Jalisco.
Ethics and Oversight
* Conducted in accordance with the Declaration of Helsinki and ICH-GCP.
* IRB/Ethics approval: Comité de etica en investigacion, Protocol CEI 214/25, Approval : October 16, 2025.
* Written informed consent obtained from all participants prior to any study procedures.
* Data

Start Date01 Dec 2025

Sponsor / Collaborator

Hospital Civil de Guadalajara

CTIS2024-516232-10-00

/ Not yet recruitingPhase 4IIT

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Start Date01 Dec 2025

Sponsor / Collaborator

Centre Hospitalier Universitaire de Nimes

100 Clinical Results associated with Sulfamethoxazole/Trimethoprim

100 Translational Medicine associated with Sulfamethoxazole/Trimethoprim

100 Patents (Medical) associated with Sulfamethoxazole/Trimethoprim

19,177

Literatures (Medical) associated with Sulfamethoxazole/Trimethoprim

01 Dec 2026·BRAZILIAN JOURNAL OF MICROBIOLOGY

Enterotoxin and biofilm producing Staphylococcus aureus and MRSA isolates from animal source foods sold in Assam

Article

Author: Av, Vishnu Raghavendran ; O R, Vinodh Kumar ; Dhanze, Himani ; Rawat, Shriya ; Dubal, Zunjar Baburao ; Kolhe, Rahul ; Kumar, Rajiv Ranjan ; Viswas, K N

Animal-derived foods (ADF) are carriers of toxin-producing multidrug-resistant (MDR) S. aureus strains, posing a global food safety risk. We evaluated the toxin and biofilm production capabilities of S. aureus isolates from ADF marketed in Assam, India. Of the 138 staphylococcal isolates, 29 (21.01%) were identified as S. aureus, mostly isolated from raw milk. Resistance to chloramphenicol (13.79%), erythromycin (68.96%), penicillin (93.10%), enrofloxacin (20.68%), tetracycline (55.17%), trimethoprim-sulfamethoxazole (20.68%), linezolid (6.89%), cefoxitin (55.17%), and oxacillin (48.27%) was noted. Approximately 82.75% isolates were MDR, whereas 27.58% carried mecA gene, indicating methicillin-resistant S. aureus. PCR toxinotyping revealed pvl (20.69%), sea (37.93%), and sed (17%) genes. Additionally, 6.89% isolates harbored seb, sei, and tst genes; all lacked eta, etb, see, seg genes. A significant difference (P < 0.05) was observed in sea and sei genes across food sources. Biofilm-forming genes were detected as icaA (65.51%), icaB (34%), icaC (48.27%), icaD (27.58%), clfA (51.72%), clfB and fnbA (44.82%). At least one biofilm-associated gene was found in 72.41% of isolates, while two or more genes were present in 80.95%. Approximately 87.5% of mecA-positive isolates contained at least one biofilm-associated gene. A significant difference (P < 0.05) was noted in icaA, icaD, clfB, and fnbA across the different ADF sources.

01 Apr 2026·Journal of Infection and Public Health

Burkholderia cepacia complex infections beyond hospital outbreaks: A 22-Year analysis of clinical characteristics, antimicrobial resistance, and mortality predictors

Article

Author: Alamro, Saud A ; Basheikh, Mohammed A ; Rahman, Jawad Ur ; Alwarthan, Sara M ; Al-Hariri, Mohammad T ; Alnimr, Amani ; AlSulaiman, Reem S ; Darweesh, Basel A ; AlShehail, Bashayer M ; Algazaq, Jumanah ; Alwazzeh, Marwan Jabr ; Alhajri, Mashael

BACKGROUND:

Burkholderia cepacia complex bacteria are intrinsically multidrug-resistant opportunistic pathogens that pose a growing threat in hospital settings, particularly among immunocompromised patients. Despite its clinical significance, data on sporadic Burkholderia cepacia complex infections outside cystic fibrosis populations and hospital outbreaks remain limited.

METHODS:

A 22-year retrospective observational cohort study (May 2001-April 2023) was carried out at a tertiary care academic center in the Eastern Province of Saudi Arabia. Adults hospitalized with confirmed Burkholderia cepacia infection and ≥ 72 h of antibiotic therapy were included. Demographics, comorbidities, infection type, microbiological resistance profiles, treatment outcomes, and mortality predictors were analyzed using logistic regression and Kaplan-Meier survival estimates.

RESULTS:

Of 189 identified cases, 151 patients met the inclusion criteria (mean age 53 ± 21 years; 57.6 % male). The majority of infections were hospital-acquired (84.8 %), with bloodstream infections (33.1 %) and ventilator-associated pneumonia (26.5 %) being the most prevalent. Resistance was high to piperacillin/tazobactam (73.6 %), ceftazidime (58.6 %), levofloxacin (57.4 %), carbapenems (42.0 %), and trimethoprim-sulfamethoxazole (30.3 %). Clinical resolution was achieved in 82.1 %, but bacteriological eradication occurred in only 56.9 %, with a recurrence rate of 17.2 %. Mortality reached 9.9 % at 14 days, 17.2 % at 30 days, and 35.8 % at one year. Independent predictors of 30-day mortality included advanced age, critical care admission, central venous catheter insertion, mechanical ventilation, and resistance to fluoroquinolones or carbapenems.

CONCLUSIONS:

Our findings indicate that Burkholderia cepacia complex infections represent a significant clinical challenge due to antibiotic resistance and elevated mortality rates. The data highlight the importance of improving diagnostic and treatment approaches, as well as implementing effective infection control policies, especially for vulnerable hospitalized populations.

01 Mar 2026·Annals of Laboratory Medicine

Prevalence and Molecular Epidemiology of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Effects of Antimicrobial Use in Multiple Pig Industry Sectors in Korea

Article

Author: Kim, Young Ah ; Seo, Young Hee ; Kim, Hyunsoo ; Lee, Kyungwon

Background:

The spread of antimicrobial-resistant bacteria has close relationships among humans, animals, and the environment, necessitating the implementation of the "One Health" approach. In previous study, the prevalence and molecular epidemiology of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) were investigated across multiple pig industry sectors in Korea. In this study, animal developmental stages and antimicrobial usage policies on farms were also considered.

Methods:

A total of 6,288 non-duplicated samples were collected from pig farms, slaughterhouses, and their personnel from three provinces in Korea between 2020 and 2022. Antimicrobial susceptibility and ESBL gene characterization were performed on the samples.

Results:

Overall, 1,084 ESBL-EC isolates were collected, with positivity detection rates of 24.7%, 23.3%, 12.7%, 3.9%, 17.2% in pigs, workers, the environment, meat, and total samples, respectively. Common ESBL types were bla_CTX-M-55 (N=628), bla_CTX-M-15 (N=204), and bla_CTX-M-14 (N=127). Pig-derived E. coli isolates had antimicrobial resistance (AMR) rates of 80.4%, 47.2%, 32.6%, 36.7%, 43.4%, 62.4%, and 72.1% to ampicillin, piperacillin, cefazoline, ciprofloxacin, cotrimoxazole, chloramphenicol, and tetracycline, respectively. AMR rates were lower in the finishing stage pigs than in the lactating stage pigs and tended to decrease during animal development for most antimicrobials. AMR rates were higher in pig farms with a customary antimicrobial use policy than in those with a low-level antimicrobial use policy.

Conclusions:

The findings highlight the significance of elucidating AMR networks among humans, animals, and the environment. Prudent antimicrobial usage and continuous AMR monitoring in the pig industry are crucial to safeguard food safety.

News (Medical) associated with Sulfamethoxazole/Trimethoprim

08 Jul 2025

·pharma.economictimes.indiatimes.com

NITI Aayog Meet: Small Drugmakers Push Back on NPPA Price Caps, Seek Financial Assistance

New Delhi: Amid rising concerns over the growing incidence of substandard drugs produced by MSME units in India, small drugmakers have argued that unsustainable price caps and insufficient financial support are undermining their ability to maintain quality and address other compliance issues. At a high-level meeting with NITI Aayog—attended by Dr. V.K. Paul, the Drug Controller General of India (DCGI), and other key officials— CIPI Chairman RK Jain concerned that the pricing regulations imposed by the National Pharmaceutical Pricing Authority (NPPA) have severely affected the margins of small manufacturers and has pushed many quality drugs out of the domestic market. “Unsustainable pricing has pushed many quality drugs out of the domestic market,” he said. The representative also urged the government to provide financial assistance to help MSME pharmaceutical firms build infrastructure for stability studies and reduce the incidence of Not of Standard Quality (NSQ) drugs. Citing the example of co-trimoxazole, he highlighted that the ceiling price set by the National Pharmaceutical Pricing Authority (NPPA) has compelled small manufacturers to discontinue its production. Co-trimoxazole, an antibiotic indicated to treat bacterial infections was added to the national list of essential medicines (NLEM) in 2022, that resulted in the average reduction of around 16 per cent. Currently, the ceiling price for co-trimoxazole oral liquid (5 ml suspension) is capped at ₹0.35 per ml, while the tablet form is priced at ₹0.9 and ₹2.3 for higher dosage strength. Under Schedule I of the Drug Price Control Order (DPCO), 2013, the NPPA regulates both bulk drugs and formulations listed in the NLEM by fixing ceiling and retail prices to ensure affordability. Marketers are allowed to raise prices in line with inflation, based on the Price Differential Index prepared by the Office of the Economic Adviser (OEA), Ministry of Commerce and Industry. Meanwhile, over the dealy in compliance with the revised schedule M norms, representatives from other lobby groups such as Laghu Udyog Bharati, FOPE, IDMA and several others presented that, “gap analysis and detailed data requirements create hindrances in filing for entitlement for many companies, as many changes occur during development.” “MSME below ₹50 crores needed hand-holding and further extension in Revised Schedule M, as well as simplification of DOP-derived RPTUAS as per Revised Schedule M or WHO Good Manufacturing Practices (GMP),” the representatives noted. The PTUAS (Pharmaceutical Technology Upgradation Assistance Scheme) is a credit-linked initiative offering up to ₹1 crore in financial aid for MSME pharma units aiming to upgrade their facilities to WHO-GMP or Schedule M standards. Besides this, the industry representatives has also called for incentivising the compliance process by offering rewarding with ₹50 lakhs to ₹2 crores to companies that successfully obtain license through joint inspections of CDSCO and state regulatory bodies. Small drugmakers are those entities who have an annual turnover of or less than ₹250 crore and of the country’s total poll of 10,500 manufacturers around 8,500 fall under the MSME category. However, according to the Ministry of Health, only 2,000 of these units are WHO-GMP certified—highlighting the urgent need for targeted policy support, infrastructure upgradation, and regulatory collaboration to ensure quality manufacturing at scale. By Abhijeet Singh ,

NDA

24 Jan 2025

·pharma.economictimes.indiatimes.com

Paracetamol among 135 drugs fails CDSCO quality test

New Delhi: During its monthly review undertaken to monitor and ensure the quality of drugs manufactured in the country, the apex drug regulator CDSCO has identified 135 drug batches including Paracetamol, Vitamin D3 supplements, anti-diabetic pills, high blood pressure etc. as ‘Not of Standard Quality’ (NSQ). Paracetamol Tab IP 500 mg which failed to meet the quality standards was picked by the Drugs Testing Laboratory Thiruvananthapuram and is manufactured by Kerala Medical Services Corporation Ltd. As per the regulators' alert the identified sample, “fails the test ‘Dissolution’ as per IP ( Indian Pharmacopoeia ).” Another Paracetamol Tablet with a dosage strength of 650 mg was manufactured by VivekPharmachem and failed to meet the quality standards when tested by the Karnataka state laboratory. It is flagged as NSQ. Paracetamol is indicated for headache, period pain and cold or flu symptoms and is easily available as over-the-counter medication. In the December drug alert, the Central Drugs Standards Control Organisation (CDSCO) declared 135 drug samples as NSQ. Among these 51’ samples were picked by the regulator’s central drug laboratories while the state laboratories identified the remaining ‘84’ NSQ samples. In the central list, the drugs and formulations which have been identified as NSQ include Paracetamol Paediatric Oral Suspension manufactured by ION Healthcare; Doxycycline capsules by Hindustan Antibiotics; Glimepiride Tablets by Life Max Cancer Laboratories; Co - trimoxazole by Omega Pharma among 47 others. The State NSQ list comprises Metformin Hydrochloride tablets manufactured by Cipla Ltd; Divalproex Extended Release tablets of Biodeal Pharmaceuticals; and Betahistine Dihydrochloride Tablets by CMG BIOTECH among 81 others. The majority of the drug batches tested by the regulator were manufactured in 2023, 2024 and were set to expire in the next two years depending upon the date of their manufacturing. As per the Health Ministry, “previous month, this month’s NSQ reporting from states has further increased showing increased participation of States in reporting NSQs to the central database.” “Increased reporting of NSQs/Spurious identifications from states to central database will further help in improving availability of quality medicines in the country and beyond,” the ministry added. The drugs that fail to meet the quality standards or specifications are listed as Not of Standard Quality (NSQ) drugs where the term ‘standards of quality’ is defined under Section 16 (1) (a) of Drugs & Cosmetics Act, 1940. By Online Bureau ,

NDA

04 Nov 2024

·www.drugs.com

Nitrofurantoin, Cranberry Products May Cut UTI Episodes in Children

MONDAY, Nov. 4, 2024 -- For children with a history of recurrent urinary tract infection (RUTI), nitrofurantoin and cranberry products may reduce the incidence of symptomatic UTI episodes, according to a review published online Nov. 4 in Pediatrics . Nikolaos Gkiourtzis, M.D., from the Aristotle University of Thessaloniki in Greece, and colleagues conducted a systematic literature review of randomized controlled trials comparing prophylaxis options for the prevention of UTI and kidney scarring in children with a history of RUTI. A total of 3,335 participants from 23 studies were included in the meta-analysis. The researchers found that cranberry products (compared with the control group) and nitrofurantoin (compared with the control, trimethoprim-sulfamethoxazole, or trimethoprim groups) led to lower odds of symptomatic UTI episodes during prophylaxis. Compared with all available documented interventions, nitrofurantoin appeared to be the best option for reduction in the incidence of UTI. None of the prophylaxis options showed a reduction in kidney scarring. "Future studies with optimal methodology, studying nonantibiotic prophylaxis options, focusing on children with RUTI, and the risk for kidney scarring are needed to draw further conclusions," the authors write. Abstract/Full Text Editorial (subscription or payment may be required) Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical Result

100 Deals associated with Sulfamethoxazole/Trimethoprim

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sulfamethoxazole/Trimethoprim	J01EE01	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Infectious Diseases	United States	Pharmaceutical Associates, Inc.	07 Jan 1983
Enteritis	Japan	Tsuruhara Pharmaceutical Co. Ltd.	24 Mar 1981
Respiratory Diseases	Japan	Tsuruhara Pharmaceutical Co. Ltd.	24 Mar 1981
Bacterial Infections	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Cystitis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Cystitis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Infectious enteritis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Paratyphoid Fever	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pneumonia	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Pneumonia	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Pyelonephritis	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Secondary infection	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	Japan	Shionogi Pharma Co., Ltd.	14 Feb 1976
Typhoid Fever	Japan	Taiyo Pharma Co., Ltd.	14 Feb 1976
Acute otitis media	United States	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Acute otitis media	United States	Monarch Pharmaceuticals LLC	30 Jul 1973
Bronchitis, Chronic	United States	Sun Pharmaceutical Industries, Inc.	30 Jul 1973
Bronchitis, Chronic	United States	Monarch Pharmaceuticals LLC	30 Jul 1973

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
HIV Seropositivity	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013
Malaria	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013
Pregnancy Complications, Infectious	Phase 3	Central African Republic	Institut Pasteur	01 Dec 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Literature Manual	Phase 2/3	Whipple Disease	64	oral doxycycline +hydroxychloroquine	piuiddwpbv(bebwasmckz) = orhaamqkhm igdlvsdbzk (tqilijqwss ) View more	Non-inferior	17 Feb 2025
				intravenous ceftriaxone+oral trimethoprim-sulfamethoxazole	piuiddwpbv(bebwasmckz) = ljzggepzgq igdlvsdbzk (tqilijqwss ) View more
NCT05418777 (CTgov)	Phase 1/2	Pulmonary Disease, Chronic Obstructive	1	Trimethoprim Sulfamethoxazole (TMP-SMX)	qufdkffzdx(coplwepgtg) = afabdnathz yhazkwypkw (iyxumzuemz, 0) View more	-	29 Nov 2023
				Placebo (Placebo)	nplexgqjbn(nlwrthsuha) = aoeidsccfu clgvcryzlp (gkdmbcfmhr, vsdtimtydj - bynhoewatn) View more
EULAR2022	Not Applicable	Rheumatic Diseases	438	Patients with AEs of SMX/TMP	evsbgkqpny(krzkjhrxhr) = qyrunvixol sdamqdgpwj (lrbforhoma ) View more	Positive	01 Jun 2022
				Patients without AEs of SMX/TMP	evsbgkqpny(krzkjhrxhr) = vmojyuglvy sdamqdgpwj (lrbforhoma ) View more
NCT03431168 (PREMISE, CTgov)	Phase 2	HIV Infections \| Malaria	308	TMPS+Azithromycin (Azithromycin/TMPS)	zkieicwtjy = befesckhpz saermkxiqc (jeehvedbvf, nbmfacmqpe - vhltwiorri) View more	-	04 May 2022
				Placebo/TMPS (Placebo/TMPS)	zkieicwtjy = sqwwqptxgp saermkxiqc (jeehvedbvf, bpewapwwar - iymrzckvrd) View more
UEGW2021	Not Applicable	Inflammatory Bowel Diseases	-	TMP/SMX prophylaxis	nkxbszyfom(srkjchqzej) = ixkvshekbk oayohwedff (yqiqvhszcd )	-	02 Oct 2021
				No TMP/SMX prophylaxis	nkxbszyfom(srkjchqzej) = ciszhcxdkk oayohwedff (yqiqvhszcd )
ATS2021	Not Applicable	COVID-19 C Reactive protein	142	Co-Trimoxazole	bcsiphqqek(kyyrxruhtn) = veqovkvhsc qokjotdmms (wqcsdwsdie, 39)	Positive	03 May 2021
NCT01650558 (Pubmed \| Clin Infect Dis)	Not Applicable	-	1,499	Continue daily co-trimoxazole	kykfpzkgad(anmhvaense) = wcpityzotf qlojqtugwl (jmbeyoctsj )	-	21 Mar 2021
				Discontinue daily co-trimoxazole and begin weekly chloroquine	kykfpzkgad(anmhvaense) = kkvcdclqas qlojqtugwl (jmbeyoctsj )
NCT02759120 (CleanUP-IPF, CTgov)	Phase 3	Idiopathic Pulmonary Fibrosis	513	No Intervention: Standard of Care	jmnbmhfulm = kivwemyftf ktjyeytipi (lrcjxejogx, dhiukohtik - kjcfosiveb) View more	-	03 Mar 2021
NCT00867789 (CTgov)	Not Applicable	Abscess	140	Trimethoprim-sulfamethoxazole (Trimethoprim-sulfamethaxazole)	sfpryigylq = jyybwiusbl mmedsrvfbq (ondpxctvco, lgainijlqt - rjcamqbybw) View more	-	26 Jan 2021
				sugar pill (Sugar Pill)	sfpryigylq = shjefmdzfm mmedsrvfbq (ondpxctvco, ldjuzvniic - vpnasvaitq) View more
NCT02773407 (Pubmed \| Clin Infect Dis)	Phase 3	Fever	326	Trimethoprim-sulfamethoxazole (SXT)	alrmlucfty(xucapoigfa) = xeysgfdhzn ursrzozmwb (effpdeqvok, 2.6 - 3.3)	Positive	29 Sep 2020
				Azithromycin	alrmlucfty(xucapoigfa) = tmxvegdmae ursrzozmwb (effpdeqvok, 1.6 - 3.2)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sulfamethoxazole/Trimethoprim

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation